Biomind Labs Inc.
BMND
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 111.35% | 122.56% | -0.81% | 6.53% | -12.69% |
| Depreciation & Amortization | -100.00% | -75.00% | -33.33% | 0.00% | 33.33% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 98.44% | 109.30% | -3.33% | -10.72% | -40.83% |
| Operating Income | -98.44% | -109.30% | 3.33% | 10.72% | 40.83% |
| Income Before Tax | -529.13% | -226.45% | 83.86% | 94.28% | 85.07% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -529.13% | -226.45% | 83.86% | 94.28% | 85.07% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -529.13% | -226.45% | 83.86% | 94.28% | 85.07% |
| EBIT | -98.44% | -109.30% | 3.33% | 10.72% | 40.83% |
| EBITDA | -102.72% | -113.50% | 2.36% | 8.74% | 40.66% |
| EPS Basic | -470.00% | -205.56% | 84.04% | 93.40% | 84.13% |
| Normalized Basic EPS | -288.89% | -217.39% | 76.67% | 86.76% | 77.50% |
| EPS Diluted | -470.00% | -205.56% | 84.04% | 93.40% | 84.13% |
| Normalized Diluted EPS | -288.89% | -217.39% | 76.67% | 86.76% | 77.50% |
| Average Basic Shares Outstanding | 1.94% | 2.89% | 3.86% | 2.72% | 1.78% |
| Average Diluted Shares Outstanding | 1.94% | 2.89% | 3.86% | 2.72% | 1.78% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |